DBV Technologies was founded in 2002 by Doctor Pierre-Henri Benhamou (specializing in Pediatric Gastroenterology), the engineer Bertrand Dupont (from the Arts et Métiers ParisTechinParis) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris).[1][3][7][8][9][10]
The founders provided initial startup capital.[3] Approximately €40M in venture funding was acquired between December, 2003 and January, 2011.[11][12] In March 2012, an initial public offering on the NYSE Euronext exchange yielded €40.5M (Euros).[2][13][14][15]
Daniel Tassé is CEO and Pascal Wotling is Chief Technical Operations Officer and Chief Quality Officer.[1][10]
DBV Technologies is focused on food allergies (milk and peanut), and pediatric allergies for which there are currently no effective treatments.[16] It has developed two products: Viaskin Peanut for the treatment of peanut allergies and Viaskin Milk for cow's milk allergies.[4][5][17]
The Viaskin Peanut treatment helps patients tolerate exposure to peanut and thus lowers the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen.[1][3][4][17]
The clinical development program for Viaskin Peanut has received "Fast Track" designation from the US Food and Drug Administration. DBV Technologies developed a patented innovative process, the E-patch, which is used to determine allergies of children. The ready-to-use standardised patch tests are highly reliable and conserve the allergic agents in their best state of allergy.[6][16][18] In September 2014, DBV Technologies announced that its VIPES (Viaskin Peanut Efficacy and Safety) clinical trial of Viaskin Peanut achieved successful results in peanut allergy desensitization.[19]
